Sarepta Therapeutics
SRPT
233 hedge funds and large institutions have $2.44B invested in Sarepta Therapeutics in 2017 Q3 according to their latest regulatory filings, with 68 funds opening new positions, 104 increasing their positions, 34 reducing their positions, and 23 closing their positions.
206% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 34
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
196% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 23
70% more capital invested
Capital invested by funds: $1.44B → $2.44B (+$1B)
23% more funds holding
Funds holding: 189 → 233 (+44)
22% more call options, than puts
Call options by funds: $312M | Put options by funds: $256M
5.81% more ownership
Funds ownership: 77.72% → 83.52% (+5.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Fred Alger Management
New York
|
+$50.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$41.3M |
| 3 |
BlackRock
New York
|
+$40.3M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$38.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$37.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$36.7M |
| 2 |
HM
HealthCor Management
New York
|
-$33.1M |
| 3 |
CCM
Cadian Capital Management
New York
|
-$20.9M |
| 4 |
TCP
Tourbillon Capital Partners
New York
|
-$15.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.2M |
SRPT Hedge Fund Activity: Q3 2017 in Review
233 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2017, worth a combined $2.44B — up 70% from $1.44B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new SRPT positions and 23 closed out — a net gain of 45 holders — while 104 added to existing stakes and 34 trimmed.
The largest buyer was Fred Alger Management, adding an estimated $50.9M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $36.7M sold.
- 233 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2017, up from 189 in Q2 2017.
- Funds reported $2.44B of Sarepta Therapeutics stock for Q3 2017, up 70% quarter-over-quarter.
- 68 funds opened new Sarepta Therapeutics positions in Q3 2017 and 23 closed out, a net change of +45 holders.
- The largest Sarepta Therapeutics buyer in Q3 2017 was Fred Alger Management, an estimated $50.9M added.
- The largest Sarepta Therapeutics seller in Q3 2017 was Perceptive Advisors, an estimated $36.7M sold.
Based on aggregated 13F filings for Q3 2017.